Zobrazeno 1 - 10
of 229
pro vyhledávání: ''
Publikováno v:
Future Oncology. 18:859-870
Objectives: To evaluate the cost–effectiveness of immune checkpoint inhibitors versus docetaxel in patients with advanced non-small-cell lung cancer. Methods: A Markov model was constructed to simulate the clinical outcomes and costs of advanced no
Autor:
Zhouwei Zhan, Xiaojie Wang, Jiami Yu, Jingxian Zheng, Yi Zeng, Mingyao Sun, Li Peng, Zengqing Guo, Bijuan Chen
Publikováno v:
Future Oncology. 18:1259-1271
Objective: To investigate the efficacy and safety of intraperitoneal administration of recombinant human endostatin in gastric cancer with malignant ascites. Methods: Clinical data of 90 patients (37 in an Endostar® combined with cisplatin group and
Autor:
Shaolei Yan, Haiyong Peng, Qiujie Yu, Xiaodan Chen, Yue Liu, Ye Zhu, Kaige Chen, Ping Wang, Yujiao Li, Xiushi Zhang, Wei Meng
Publikováno v:
Future Oncology. 18:991-1001
Background: To determine suitable optimal classifiers and examine the general applicability of computer-aided classification to compare the differences between a computer-aided system and radiologists in predicting pathological complete response (pCR
Publikováno v:
Future Oncology. 18:1273-1284
Aim: To investigate the association between receiving treatment at academic centers and overall survival in pancreatic ductal adenocarcinoma patients who do not receive definitive surgery of the pancreatic tumor. Methods: Using the National Cancer Da
Autor:
Kathryn Tremble, Louis Fox, Charlotte Moss, Beth Russell, Haleema Aljazzaf, Finola Higgins, Bill Dann, Vikash Jogia, Graham Roberts, Anne Rigg, Saoirse Dolly, Mieke Van Hemelrijck
Publikováno v:
Future Oncology
Objective: The authors monitored positivity rates of asymptomatic SARS-CoV-2 tests during the second wave of COVID-19 at Guy's Cancer Centre. Methods: Logistic regression was used to investigate factors associated with asymptomatic COVID positivity r
Autor:
Rebecca L Stone, M Janelle Cambron-Mellott, Kathleen Beusterien, Martine C Maculaitis, Stephanie Ritz, Emily Mulvihill, Matthew Monberg, Elizabeth A Szamreta, Suvina Amin, Kimmie McLaurin
Publikováno v:
Future Oncology. 18:491-503
Plain language summary Maintenance therapy is a treatment option intended to keep ovarian cancer from coming back or getting worse for as long as possible after responding to chemotherapy. PARP inhibitors are a new type of maintenance therapy for ova
Publikováno v:
Future Oncology
Introduction: The objective of this study was to evaluate the clinical and laboratory outcomes of solid cancer patients who were reinfected with COVID-19. Methods: Patients who were tested negative on the Coronavirus disease 2019 (COVID-19) PCR test
Autor:
Ariadna Juarez-Garcia, John C O'Donnell, John R. Penrod, Mats Rosenlund, Simon Ekman, Jens Benn Sørensen, Anne Mette Kejs, Pia Horvat, L. Lacoin, Odd Terje Brustugun, Dony Patel, M. Daumont
Publikováno v:
Sørensen, J B, Horvat, P, Rosenlund, M, Kejs, A M, Patel, D, Juarez-Garcia, A, Lacoin, L, Daumont, M J, Penrod, J R, O'donnell, J C, Brustugun, O T & Ekman, S 2022, ' Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015) : SCAN-LEAF study ', Future Oncology, vol. 18, no. 2, pp. 205-214 . https://doi.org/10.2217/fon-2021-0746
Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagn
Autor:
Shigemasa Takamizawa, Yoshitaka Zenke, Shingo Kitagawa, Taiki Hakozaki, Yasuhiro Kato, Yusuke Okuma
Publikováno v:
Future Oncology. 18:291-300
Background: The efficacy of osimertinib as a first-line treatment for patients with poor performance status (PS) remains unclear. Patients & methods: This multicenter retrospective study evaluated patients treated with osimertinib between 2018 and 20
Publikováno v:
Future Oncology. 18:47-54
Aims: To review the patterns of early-onset (